CNCE
Closed
Concert Pharmaceuticals Inc
8.37
+0.01 (+0.12%)
Last Update: 06 Mar 2023 17:30:00
Yesterday: 8.36
Day's Range: 8.37 - 8.37
Send
sign up or login to leave a comment!
When Written:
8.37
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, USA. The company was founded in 2006 and is focused on developing new drugs that address unmet medical needs in various therapeutic areas, including central nervous system (CNS) disorders, inflammation, and oncology.
Concert Pharmaceuticals uses a proprietary technology platform called deuterium chemistry to modify existing drugs and create new chemical entities with improved pharmacokinetic properties. This platform allows the company to develop drugs that have better efficacy, safety, and tolerability profiles than existing treatments.
The company's pipeline includes several drug candidates in various stages of development, including CTP-543 for alopecia areata, a chronic autoimmune disorder that causes hair loss; CTP-692 for schizophrenia, a severe mental illness that affects about 1% of the population worldwide; and CTP-692 for major depressive disorder, a common mental health condition that affects millions of people worldwide.
Concert Pharmaceuticals has collaborations with several leading pharmaceutical companies, including Celgene, Avanir Pharmaceuticals, and Jazz Pharmaceuticals. The company has also received funding from various sources, including venture capital firms, government agencies, and foundations.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Concert Pharmaceuticals uses a proprietary technology platform called deuterium chemistry to modify existing drugs and create new chemical entities with improved pharmacokinetic properties. This platform allows the company to develop drugs that have better efficacy, safety, and tolerability profiles than existing treatments.
The company's pipeline includes several drug candidates in various stages of development, including CTP-543 for alopecia areata, a chronic autoimmune disorder that causes hair loss; CTP-692 for schizophrenia, a severe mental illness that affects about 1% of the population worldwide; and CTP-692 for major depressive disorder, a common mental health condition that affects millions of people worldwide.
Concert Pharmaceuticals has collaborations with several leading pharmaceutical companies, including Celgene, Avanir Pharmaceuticals, and Jazz Pharmaceuticals. The company has also received funding from various sources, including venture capital firms, government agencies, and foundations.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!